Drug intelligence / Profile preview

IVL5006

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Peptides
Administration: Parenteral

Overview

IVL5006 is a preclinical-stage long-acting injectable (LAI) peptide therapeutic being developed by Inventage Lab in collaboration with Boehringer Ingelheim. The program utilizes Inventage Lab's proprietary IVL-DrugFlow platform, which employs microsphere-based technology to enable the sustained release of peptide drugs. This formulation approach is designed to transform daily or frequent injections into monthly or multi-month administrations, potentially enhancing patient adherence and maintaining stable therapeutic drug levels. As of 2024, the specific biological target and therapeutic indication for IVL5006 remain undisclosed.

Beyond the preview

Go deeper on IVL5006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVL5006.

Explore the full profile